Vico Therapeutics
CompanyNetherlands
Vico Therapeutics develops one asset, in phase 2 (VO659 in 3 and Huntington's disease spinocerebellar ataxia types 1). Mostly oligonucleotide; based in Netherlands.
- 1
- Asset
- Furthest stage
- Phase 2
- Raised
- €65.8M + $60M
- 1
- Trial
- 1
- Signal
Pipeline
1Antisense oligonucleotide targeting expanded CAG-repeat RNA to reduce production of toxic polyglutamine proteins.
Phase 2, Oligonucleotide, 3 and Huntington's disease spinocerebellar ataxia types 1
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Trials1
- Funding rounds and grants2
- Signals1
- Similar companies6